382 related articles for article (PubMed ID: 33015092)
1. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting.
Pavlych V; Di Muzio C; Alunno A; Carubbi F
Front Med (Lausanne); 2020; 7():534. PubMed ID: 33015092
[No Abstract] [Full Text] [Related]
2. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
6. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
7. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
[TBL] [Abstract][Full Text] [Related]
8. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
11. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome.
Ture HY; Kim NR; Nam EJ
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895373
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
Suh CH; Yoo DH; Berrocal Kasay A; Chalouhi El-Khouri E; Cons Molina FF; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Linde T; Hrycaj P; Abello-Banfi M; Hospodarskyy I; Jaworski J; Piotrowski M; Brzosko M; Krogulec M; Shevchuk S; Calvo A; Andersone D; Park W; Shim SC; Lee SJ; Lee SY
BioDrugs; 2019 Feb; 33(1):79-91. PubMed ID: 30719632
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
14. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
[TBL] [Abstract][Full Text] [Related]
16. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
[TBL] [Abstract][Full Text] [Related]
18. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis.
Yoo DH; Suh CH; Shim SC; Lee SJ; Kim SH; Park W
Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1125-1132. PubMed ID: 33012214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
